Compare Arqit Quantum Inc (ARQQ) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs DexCom, Inc. — how do they compare? Arqit Quantum Inc trades at $17.8 (market cap $332.04M), while DexCom, Inc. trades at $75.83 (market cap $28.93B). The key difference: DexCom, Inc. is far larger — about 87.1× Arqit Quantum Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | DXCM | |
|---|---|---|
Market Cap | $332.04M | $28.93B |
Sector | Technology | Health |
52-Week High | $58.27 | $89.53 |
52-Week Low | $11.78 | $54.84 |
Enterprise Value | $305.35M | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
